subscribeSubscribe
Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients

Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients
BUSINESSWIRE
07 Sep 2022
Share Share
Merck Europe B.V. Tepmetko(tepotinib) Receives Approval in Europe

Merck Europe B.V. Tepmetko(tepotinib) Receives Approval in Europe
EMA
05 May 2022
Share Share
EC Approves TEPMETKO in Advanced NSCLC with METex14 Skipping Alterations

EC Approves TEPMETKO in Advanced NSCLC with METex14 Skipping Alterations
BUSINESSWIRE
18 Feb 2022
Share Share
TEPMETKO Receives Positive CHMP Opinion in Advanced NSCLC

TEPMETKO Receives Positive CHMP Opinion in Advanced NSCLC
BUSINESSWIRE
17 Dec 2021
Share Share
MHRA backs Merck’s MET inhibitor Tepmetko

MHRA backs Merck’s MET inhibitor Tepmetko
Lucy Parsons PHARMATIMES
13 Oct 2021
Share Share
EMD Serono to Highlights From Oncology Portfolio at WCLC & ESMO 2021

EMD Serono to Highlights From Oncology Portfolio at WCLC & ESMO 2021
BUSINESSWIRE
13 Sep 2021
Share Share
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval

AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval
GLOBENEWSWIRE
16 Aug 2021
Share Share
Merck’s MET inhibitor tepotinib gains positive opinion from MHRA

Merck’s MET inhibitor tepotinib gains positive opinion from MHRA
Lucy Parsons PHARMATIMES
15 Jul 2021
Share Share
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor

FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor
PRNEWSWIRE
03 Feb 2021
Share Share
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor

FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor
PRNEWSWIRE
03 Feb 2021
Share Share